pre-clinical
Make cost-effective decisions on pre-clinical advancement using DARC
DARC provides early insight on your asset’s MOA and dose-response relationship, as well as help optimise drug delivery methods
DARC is capable of objectively informing whether to progress an asset to clinical trial, helping to bridge the pre-clinical and clinical gap
DARC helps indicate the potential effectiveness of your ophthalmic asset, allowing you to make rapid, cost-effective decisions.
Maximise trial success
Our specialist DARC team can determine the efficacy of your early-stage therapeutics
interested?
Book a MEETING WITH OUR EXPERTS TODAY
Dr. Alex Wilson,
Director of Corporate
Development & Quality
our publications
See below a sample of our research papers, click to read